Evidence map›Paper›PMID 28797035›Full record

Trial reportPloS one2017

Protein expression patterns of cell cycle regulators in operable breast cancer.

Flora Zagouri, Vassiliki Kotoula, George Kouvatseas, Maria Sotiropoulou, Triantafyllia Koletsa, Theofani Gavressea, Christos Valavanis, Helen Trihia, Mattheos Bobos, Georgios Lazaridis and 14 more

Open access · goldAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 13 institutions in 1 country.

Flora ZagouriDepartment of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.ORCID http://orcid.org/0000-0001-7153-6556
Vassiliki KotoulaDepartment of Pathology, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine, Thessaloniki, Greece.
George KouvatseasHealth Data Specialists Ltd, Athens, Greece.
Maria SotiropoulouDepartment of Pathology, Alexandra Hospital, Athens, Greece.
Triantafyllia KoletsaDepartment of Pathology, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine, Thessaloniki, Greece.
Theofani GavresseaDepartment of Pathology, Iaso Women's Hospital, Athens, Greece.
Christos ValavanisDepartment of Pathology, Metaxas Cancer Hospital, Piraeus, Greece.
Helen TrihiaDepartment of Pathology, Metaxas Cancer Hospital, Piraeus, Greece.
Mattheos BobosLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.
Georgios LazaridisDepartment of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki, School of Health Sciences, Faculty of Medicine, Thessaloniki, Greece.
Angelos KoutrasDivision of Oncology, Department of Medicine, University Hospital, University of Patras Medical School, Patras, Greece.
George PentheroudakisDepartment of Medical Oncology, Ioannina University Hospital, Ioannina, Greece.
Pantelis SkarlosDepartment of Radiotherapy, Metropolitan Hospital, Piraeus, Greece.
Dimitrios BafaloukosFirst Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece.
Niki ArnogiannakiDepartment of Surgical Pathology, Agios Savas Anticancer Hospital, Athens, Greece.
Sofia ChrisafiLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.
Christos ChristodoulouSecond Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece.
Pavlos PapakostasOncology Unit, Hippokration Hospital, Athens, Greece.
Gerasimos AravantinosSecond Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece.
Paris KosmidisSecond Department of Medical Oncology, Hygeia Hospital, Athens, Greece.
Charisios KaranikiotisDepartment of Medical Oncology, 424 Army General Hospital, Thessaloniki, Greece.
George ZografosBreast Unit, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
Christos PapadimitriouDepartment of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.
George FountzilasLaboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece.
Aristotle University of Thessaloniki · GRMetropolitan Hospital · GRNational and Kapodistrian University of Athens · GRMetaxa Hospital · GR424 General Military Hospital · GRAlexandra Hospital · GRHippocration General Hospital · GRHospital Agioi Anargyroi · GRHygeia Hospital · GRIaso Children’s Hospital · GRSt Savas Hospital · GRUniversity Hospital of Ioannina · GRUniversity of Patras · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND-

aimTo evaluate the prognostic role of elaborate molecular clusters encompassing cyclin D1, cyclin E1, p21, p27 and p53 in the context of various breast cancer subtypes.

methodsCyclin E1, cyclin D1, p53, p21 and p27 were evaluated with immunohistochemistry in 1077 formalin-fixed paraffin-embedded tissues from breast cancer patients who had been treated within clinical trials. Jaccard distances were computed for the markers and the resulted matrix was used for conducting unsupervised hierarchical clustering, in order to identify distinct groups correlating with prognosis.

resultsLuminal B and triple-negative (TNBC) tumors presented with the highest and lowest levels of cyclin D1 expression, respectively. By contrast, TNBC frequently expressed Cyclin E1, whereas ER-positive tumors did not. Absence of Cyclin D1 predicted for worse OS, while absence of Cyclin E1 for poorer DFS. The expression patterns of all examined proteins yielded 3 distinct clusters; (1) Cyclin D1 and/or E1 positive with moderate p21 expression; (2) Cyclin D1 and/or E1, and p27 positive, p53 protein negative; and, (3) Cyclin D1 or E1 positive, p53 positive, p21 and p27 negative or moderately positive. The 5-year DFS rates for clusters 1, 2 and 3 were 70.0%, 79.1%, 67.4% and OS 88.4%, 90.4%, 78.9%, respectively.

conclusionsIt seems that the expression of cell cycle regulators in the absence of p53 protein is associated with favorable prognosis in operable breast cancer.

Indexed as

AdultAgedAntineoplastic AgentsBreastBreast NeoplasmsCyclin D1Cyclin-Dependent Kinase Inhibitor p21Cyclin-Dependent Kinase Inhibitor p27Cyclin EFemaleHumansImmunohistochemistryMiddle AgedOncogene ProteinsPrognosisSurvival AnalysisAntineoplastic AgentsCCND1 protein, humanCCNE1 protein, humanCDKN1A protein, humanCyclin D1Cyclin-Dependent Kinase Inhibitor p21Cyclin-Dependent Kinase Inhibitor p27Cyclin EOncogene ProteinsTumor Suppressor Protein p53

Identifiers

PMID28797035
PMCPMC5552326
OpenAlexW2742598198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.